You are here: Industry Insights > Janssen

News List

US expand use of Janssen's Darzalex pharmatimes
August 21, 2020
US regulators have approved Janssen's Darzalex (daratumumab) in combination with carfilzomib and dexamethasone (DKd) for the treatment of adults with relapsed/refractory multiple myeloma who have received one to three previous lines of therapy.
BioSymetrics, Janssen Enter AI Prediction Alliance for COVID-19 contractpharma
August 20, 2020
Will focus on predicting the onset and severity of COVID-19 among different populations using machine learning.
GeneCentric Therapeutics signs research alliance with Janssen pharmaceutical-technology
August 14, 2020
GeneCentric Therapeutics and Janssen Research & Development have formed a research alliance focused on RNA-based drug response biomarkers for non-muscle invasive bladder cancer (NMIBC).
Janssen Announces Approval of SPRAVATO for Major Depressive Disorder with Acute Suicidal Ideation americanpharmaceuticalreview
August 10, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant.
US FDA approves SPRAVATO, antidepressant medication from J&J expresspharma
August 05, 2020
The drug indicated to treat adults with major depressive disorder and acute suicidal ideation or behaviour reportedly begins improving depressive symptoms with the first dose.
US expands scope of Janssen's Stelara pharmatimes
August 04, 2020
Janssen's Stelara (ustekinumab) has been approved in the US as a treatment for paediatric patients (six-11 years of age) who struggle with the skin lesions or plaques associated with moderate to severe plaque psoriasis.
Genmab/Janssen’s Darzalex combo hits the mark in phase 3 study pharmatimes
August 04, 2020
Genmab and Janssen’s subcutaneous formulation of Darzalex (daratumumab) in combination with pomalidomide and dexamethasone (Pd) has generated positive results in a phase 3 myeloma trial.
Janssen gets CHMP positive opinion for expanded use of IMBRUVICA, rituximab combo in CLL pharmaceutical-business-review
July 29, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for IMBRUVICA ...
Janssen/MeiraGTx sight loss gene therapy hits targets pharmatimes
July 21, 2020
Janssen has unveiled six-month data from an ongoing Phase I/II trial of its investigational gene therapy for the treatment of inherited retinal disease X-linked retinitis pigmentosa (XLRP).
Janssen's Tremfya wins psoriatic arthritis approval pharmatimes
July 16, 2020
Janssen's Tremfya (guselkumab) has been approved in the US as the first selective interleukin (IL)-23 inhibitor for adults with active psoriatic arthritis (PsA).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page